ArticleVaccine: X2025

Neutralizing antibody response to SARS-CoV-2 variants, as determined by the MSD multiplex assay, following COVID-19 vaccination in cancer patients.

Christopher W Dukes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.